ClinicalTrials.gg
TerminatedNCT06910839Updated Aug 7, 2025

Study to Learn About How the Study Medicines Called PF-07976016 and PF-06882961 Are Taken Up by the Body, and if Either of Them Change How the Body Processes the Other Medicine in Otherwise Healthy Adults With Overweight or Obesity

A Phase 1 interventional study of PF-07976016 and PF-06882961 in Overweight and Obesity, sponsored by Pfizer. Terminated at 1 site in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-08-07.

Primary conditionObesityRegistry: OverweightReclassifiedWhy we changed it
Registry
Overweight — the first condition term the registry derived for this study.
ClinicalTrials.gg
Obesity
Why
  1. The study's listed conditions name Obesity, a narrower term within Overweight.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Pfizer · Phase 1, Interventional, and Basic science

Why this study was terminated
The sponsor has made the decision to discontinue development of danuglipron (PF-06882961). As such, this study was discontinued prior to PF-06882961 administration.

From the registry’s dates

  • Primary completion was May 2025, 1 year 6 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
21
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 64 studies in Obesity by Pfizer — 13 open to participants now, 19 under way, 12 of them phase 3. Obesity · Pfizer.

Enrollment
55th of 62
21 · median 127
Started
2025
with 4 others
Phase 1
30 of 64
3 open now
Registered
40th of 64
by date

Among the 64 studies in Obesity by Pfizer, this one is the 55th largest by enrollment of the 62 interventional ones that give a count, is one of 5 that started in 2025, is one of 30 in phase 1, and was the 40th registered.

Obesity

11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.

Browse Obesity studies →

Open to participants now

13 of the 64 studies in Obesity by Pfizer are open now, in 12 countries. Recruiting first, the newest first:

8 more — sign in →

By country, each count listing its studies:

All 13 open studies →

Who these studies take

Of the 1,342 Obesity studies recruiting now, 377 (28%) set no upper age limit and 861 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 64 studies in Obesity by Pfizer, or all of them as a file.
02

Study summary

The purpose of this study is to see how two study medicines, PF-07976016 and danuglipron, taken together affect the level of each other in the blood of participants who have overweight or obesity.

The total number of weeks of the study is up to approximately 22 weeks (5.5 months).

03

Conditions studied

  • Overweight
  • Obesity

Browse trials for

04

In context

Obesity Reclassified

11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.

This study's enrollment of 21 is below the median of 67 across 9,023 interventional studies indexed under Obesity.

Browse Obesity studies →

Lead sponsor

Pfizer is the lead sponsor of 3,337 studies on the registry; 148 are open to participants now.

Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.

Compared within Obesity, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Overweight. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and non-pregnant, non-breastfeeding female, 18 to 65 years of age
  • 25 to 40 kg/m2 and a total body weight > 50 kg (110 lb)
  • Willing and able to comply with all study procedures including staying a research unit for up to 95 days

Exclusion criteria

Exclusion Criteria:

  • Any medical or psychiatric condition or laboratory abnormality, or recent serious illness or hospitalization, that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study including diagnosis of type 2 diabetes mellitus, type 1 or secondary forms of diabetes
  • Use of any prohibited prior or concomitant medication(s)
  • Presence of specified abnormalities on diagnostic assessments including clinical laboratory tests
  • A positive urine drug test.
  • History of alcohol abuse or repeated binge drinking and/or any other illicit drug use or dependence
  • Use of tobacco/nicotine containing products in excess of the equivalent of 5 cigarettes/day or 2 chews of tobacco/day
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

06

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
21 participants (actual)

Study arms

  • Experimental
    Period 1

    Participants will receive doses of PF-07976016 with and without PF-06882961

    Drug: PF-07976016 · Drug: PF-06882961

Interventions

07

What researchers measure

Primary outcomes

  1. Steady state area under the concentration-time profile for PF-07976016

    Time frame: From 0 Hours to 24 Hours following steady-state dose

  2. Steady state maximum observed concentration (Cmax) for PF-07976016

    Time frame: From 0 Hours to 24 Hours following steady-state dose

  3. Steady state area under the concentration-time profile danuglipron

    Time frame: From 0 Hours to 24 Hours following steady-state dose

  4. Steady state maximum observed concentration (Cmax) for danuglipron

    Time frame: From 0 Hours to 24 Hours following steady-state dose

Secondary outcomes

  1. Number of participants with treatment emergent adverse events

    Time frame: First dose (Day 1) through 28-35 days after final dose (approximately 18 weeks)

08

Study locations

1 site
  • Anaheim Clinical Trials, LLC
    Anaheim, California 92801, United States
09

References and documents

Individual participant data

Plan to share: No — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2025 to primary completion in May 2025, 1 month.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 12, 2025
First posted
Apr 4, 2025
StartActual
Mar 13, 2025
Primary completionActual
May 1, 2025
CompletionActual
May 20, 2025
Last update
Aug 7, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 7, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06910839
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Apr 4, 2025
Start date
Mar 13, 2025
Primary completion
May 1, 2025
Completion
May 20, 2025
Last update
Aug 7, 2025

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: PF-07976016 · Danuglipron

Start the discussion